March 19, 2024
Mitsubishi Tanabe Pharma said on March 18 that it has obtained Japanese regulatory approval for an OD tablet formulation of its SGLT2 inhibitor Canaglu (canagliflozin). The green light, granted on March 15, will make it the first SGLT2 inhibitor in...read more